Matsuoka Ken-Ichi
Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School.
Rinsho Ketsueki. 2024;65(9):1148-1154. doi: 10.11406/rinketsu.65.1148.
Treatment for chronic graft-versus-host disease, the most important long-term complication of allogeneic hematopoietic cell transplantation, has changed significantly over the past decade. Development of novel targeted therapies has advanced as objective criteria for the diagnosis and evaluation of chronic GVHD have been established and understanding of the biological pathways to pathogenesis has increased. This paradigm shift is driving chronic GVHD practice significantly toward individualized therapy while minimizing exposure to steroids. Treatment using a variety of novel agents, tailored to each individual patient's condition, is expected to improve quality of life and overall survival by preventing chronic GVHD, controlling disease progression, and maintaining motor and occupational functions. This article reviews the pathogenesis of chronic GVHD and discusses prospects for the treatment of chronic GVHD, along with recently approved drugs and promising drugs in development.
慢性移植物抗宿主病是异基因造血细胞移植最重要的长期并发症，在过去十年中，其治疗方法发生了显著变化。随着慢性移植物抗宿主病（GVHD）诊断和评估的客观标准的确立，以及对发病机制生物学途径认识的增加，新型靶向治疗方法不断发展。这种模式转变正推动慢性移植物抗宿主病的治疗显著朝着个体化治疗方向发展，同时尽量减少类固醇的使用。根据每位患者的病情量身定制使用各种新型药物的治疗方法，有望通过预防慢性移植物抗宿主病、控制疾病进展以及维持运动和职业功能来提高生活质量和总体生存率。本文综述了慢性移植物抗宿主病的发病机制，并讨论了慢性移植物抗宿主病的治疗前景，以及最近获批的药物和正在研发的有前景的药物。
